aap Implantate AG
- WKN: A3H210
- ISIN: DE000A3H2101
- Land: Deutschland
Nachricht vom 09.10.2020 | 11:18
Q3/2020: Capital reduction successfully implemented; sales in Q3/2020 almost stable despite continued negative impact of COVID-19; strong growth in US business (+68%) and recovery tendencies in Europe
DGAP-News: aap Implantate AG
/ Key word(s): Quarter Results/Preliminary Results
The COVID-19 pandemic continued to impair business operations at aap Implantate AG ("aap" or the "Company") in recent months, as reflected in the sales trend in the third quarter and the first nine months of 2020. Contrary to this trend, aap continued to record a clearly positive business development in the U.S. and showed dynamic growth on both a quarterly and nine-month basis. In addition, following the easing of COVID-19 measures in the third quarter, the German and European markets (excluding Germany) showed signs of recovery that were reflected in almost equal or even higher sales year-on-year. According to preliminary figures, sales in the third quarter of 2020 were thus almost at the level of the previous year at EUR 2.6 million (Q3/2019: EUR 2.7 million) and in the first nine months of the current financial year at EUR 6.9 million (9M/2019: EUR 8.7 million). Based on the sales development in Q3/2020 and the lower cost level as a result of the comprehensive restructuring and efficiency improvement program, the Management Board expects a significantly improved EBITDA and Recurring EBITDA for the third quarter of 2020.
The sales development in the first nine months was visibly influenced by the COVID-19 pandemic and the corresponding lockdown measures of the first half year, which is reflected in significantly lower sales compared to the previous year. It should also be noted that even if normality returns, there will be no catch-up effects, as in the consumer goods industry, for example, but at most a return to pre-crisis levels.
In the U.S., by contrast, aap continues on a dynamic growth course and was able to increase sales significantly year-on-year in both the third quarter (+68%) and the nine-month period (+43%). This is even more remarkable given that the U.S. is the country with the highest number of COVID-19 infections worldwide. Here, the sales momentum of the first half of the year was maintained and the number of weekly surgeries was sustainably stabilized at a level of up to 50 procedures. In addition, focused efforts to conclude contracts with nationally active companies that give aap access to a U.S. network of clinics and surgical operation centers continue to bear fruit. Overall, aap is aiming for a year-on-year sales increase of at least 30% in the U.S. in the financial year 2020 despite COVID-19.
As part of the comprehensive restructuring and refinancing process, the Management Board proposed an ordinary capital reduction in the ratio of 10:1 to aap's shareholders at the Annual General Meeting on August 7, 2020, which was approved by a large majority. The capital reduction was entered into the commercial register on October 5, 2020. Together with the complete placement of the convertible bond, two key elements of the financial restructuring and refinancing were thus successfully implemented. At present, the technical execution of the capital reduction is being carried out from the German stock exchange, so that the adjustment of the share price to the effects of the capital reduction should be carried out soon. On this basis, the Management Board of the Company is currently evaluating further capital measures (e.g. capital increase or further convertible bonds) to secure the financing of the Company in the long term.
The figures contained in this press release are preliminary figures as of September 30, 2020, which may still change before its final publication. aap plans to announce the final results for the third quarter and first nine months of 2020 in a press release in the first half of November.
aap Implantate AG; Fabian Franke; Manager Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49/30/750 19 - 134; Fax: +49/30/750 19 - 290; email@example.com
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1139931|
|End of News||DGAP News Service|
aap completes Management Board transition to s ...
aap's successful restructuring paves way for f ...
Q3 and 9M/2020: aap restructuring shows clear ...
aap Implantate AG: Significant year-on-year im ...
aap: General data for bank technical implement ...
Der spezialisierte „Bondpicker“: Deutscher Mittelstandsanleihen Fonds
Der offene Rentenfonds investiert hauptsächlich in ausgewählte Anleihen von Unternehmen des deutschen Mittelstands. Das Kernstück des Investment-Ansatzes ist das KFM-Scoring-Modell, das speziell für diesen Mittelstandssektor entwickelt wurde. Durch das sehr erfahrene aktive Fondsmanagement und den bewährten Anlagestil, sollte dem Anleihefonds auch zukünftig eine deutliche Outperformance gegenüber der allgemeinen Entwicklung am Mittelstandsanleihenmarkt gelingen.
Der AKTIONÄR News
17. Januar 15:15 BioNTech: Erst Riesenärger, dann gleich doppelt sensationelle News
17. Januar 15:00 Aktionär-Indizes: Batterie-Index schmeißt Turbo an
17. Januar 14:03 Amazon, Walt Disney und Co: So geht es weiter
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Hinzufügen Valneva SE
15. Januar 2021